BSX
HealthcareBoston Scientific Corporation
$95.48
+$0.77 (+0.81%)
Jan 5, 2026
Price History (1Y)
Analysis
Boston Scientific Corporation is a healthcare company operating in the medical devices industry. The firm is part of the broader healthcare sector and has a significant market presence, with a market capitalization of $141.54B, annual revenues of $19.35B, and approximately 53,000 employees. The company's financial health appears robust, with notable profitability metrics. Boston Scientific reports gross margins of 68.3%, operating margins of 20.7%, and profit margins of 14.4%. Additionally, the firm has demonstrated strong returns on equity (12.5%) and assets (5.8%). However, its balance sheet shows a substantial debt-to-equity ratio of 50.97% and cash holdings of $1.28B. Valuation metrics indicate that Boston Scientific trades at a relatively high price-to-earnings ratio of 50.79 (TTM) and forward P/E of 27.52. The company's revenue growth has been robust, with a year-over-year increase of 20.3%. Earnings growth has also been impressive, increasing by 60.0% over the same period. Notably, the firm does not pay dividends to its shareholders, as reflected in a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $141.54B
- P/E Ratio
- 50.79
- 52-Week High
- $109.50
- 52-Week Low
- $85.98
- Avg Volume
- 8.72M
- Beta
- 0.67
Company Info
- Industry
- Medical Devices
- Exchange
- NYQ
- Country
- United States
- Employees
- 53,000